Testicular cancer trials

AI-generated summary

This is a randomized, single-blinded trial comparing the standard inguinal radical orchiectomy with an external oblique fascia sparing version for suspected testicular cancer. It aims to test whether sparing the external oblique fascia reduces postoperative pain, narcotic use, neuropathic pain, and complications. The study is for adults undergoing radical orchiectomy who are not currently using opioids. Participants are randomly assigned to one of the two surgical techniques to see which approach offers better postoperative outcomes. Exclusions include advanced disease (clinical T4), prior illicit substance or opioid abuse, recent chemotherapy or radiotherapy, opioid use within 1 month, and very large testicular masses requiring non-standard incisions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests GV20-0251 to see if it is safe in adults with advanced or refractory solid tumors. It is a single-center, single-arm early-stage trial at West China Hospital. It uses a 3+3 dose-escalation design, starting with 10 mg/kg and 20 mg/kg given every three weeks, to find a tolerable dose and watch for dose-limiting toxicities. The trial covers multiple solid tumor types to learn about safety and dosing across indications. Key exclusions include active infections, certain heart problems or QT prolongation, autoimmune disease needing immunosuppressive therapy, HIV/HBV/HCV infections, pregnancy, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer is being studied. Conditions: Testicular Cancer • Eligibility: Inclusion Criteria: * Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND) Exclusion Criteria: * History of RPLND * Lack of consent. Goal: This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jagiellonian University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study will collect data to understand quality of life and functional/oncological outcomes in testicular cancer by building a long-term database. It is for adults over 18 who have suspected or confirmed testicular cancer and require surgery or removal of retroperitoneal lymph nodes, and who can give informed consent. The aim is to improve knowledge about the disease and help develop better diagnosis and treatment approaches based on follow-up data. Exclusion: anyone under 18 or anyone with a mental or physical disability that would prevent participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Pedmark sodium thiosulfate to protect against cisplatin-related hearing loss. - It is for adults with cancer who have not been treated yet and are going to receive a cisplatin-based chemotherapy regimen. - The study aims to learn whether sodium thiosulfate is safe and effective at reducing hearing impairment in adults, an use already shown in children but less studied in adults. - Key exclusions include prior cisplatin exposure, planned head or neck radiation, pregnancy or breastfeeding, ongoing ototoxic medications, and certain electrolyte problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether a virtual support platform can improve well-being and survivorship for men with testicular cancer. It will enroll men in North Carolina who are within five years of their germ cell testicular cancer diagnosis. Participants will be randomly assigned to either access the virtual support platform or receive educational materials, and researchers will compare emotional well-being, self-efficacy, financial toxicity, and quality of life at 3 and 6 months after baseline. The trial is not yet recruiting. Exclusions include women, non-English speakers, people unable to consent, and those currently undergoing active treatment for another cancer or for testicular cancer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor +2 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. For subjects with GCTs, age ≥15 years * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or…. Goal: The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a longitudinal cohort study to see if cancer treatment accelerates early aging in adolescents and young adults with cancer, by measuring aging markers before therapy and one year later. It includes patients aged 18-39 with a confirmed cancer diagnosis who are about to start systemic therapy with curative intent. The main goal is to see how the senescence marker P16 changes over one year, and it also looks at SASP, vascular markers, and cardiovascular risk factors related to treatment and patient/tumor characteristics. Measurements are taken at two visits and include blood tests and a physical exam (weight, height, waist-hip ratio, blood pressure); key exclusions are inability to understand consent, treatment with immune checkpoint inhibitors or anti-angiogenic therapy, and prior systemic therapy or radiotherapy for another cancer (with limited exceptions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The SEA-CAT study investigates whether cisplatin-based chemotherapy for testicular cancer increases aging-related changes by raising senescent cells and SASP (pro-inflammatory signals). It aims to learn whether this is linked to late treatment effects and an early ageing phenotype in survivors. The study has two parts: a cross-sectional group of men diagnosed with metastatic testicular cancer (stage II or higher) between 1999–2012 who received first-line cisplatin-based chemotherapy and were under 50 at the start, and a longitudinal group of men about to start first-line cisplatin-based chemotherapy, plus a stage I control group under 50 at diagnosis. Exclusion criteria include not being able to provide informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests ACOU085 injections into the middle ear to prevent hearing loss caused by cisplatin in men with testicular cancer. - It is a randomized, double-blind, placebo-controlled, multicenter Phase IIa study to evaluate effectiveness, safety, and tolerability of ACOU085 given before each of three planned chemotherapy cycles. - Each participant will receive ACOU085 in one ear and a placebo in the other ear, using the ear with the real drug as the treatment and the opposite ear as the control. - Eligible participants are adult men (18-45) with testicular cancer who will receive at least 300 mg/m2 of cisplatin over three cycles and who have normal baseline hearing; key exclusions include genetic predisposition to hearing loss, certain ear diseases or surgeries, use of other ototoxic drugs, prior cochlear radiation, and significant health problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The TACkLE Study tests risk factors for cardiovascular disease after treatment for testicular cancer and looks at whether platinum chemotherapy contributes to cardiometabolic problems. - It is a multicenter case-cohort study that includes patients treated for testicular cancer who later developed heart disease (cases) and a random sample of other treated patients (the subcohort). - Participants will complete questionnaires and donate a blood sample for DNA analysis, with basic cardiovascular risk assessments; some non-invasive tests are performed only at the UMCG. - Eligibility includes being alive, diagnosed with testicular cancer between 1976 and 2007, treated at participating centers, and younger than 50 at TC diagnosis; excluded are individuals with a mental disorder preventing consent and those with active malignant disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether prenatal exposure to endocrine-disrupting chemicals is linked to a higher risk of testicular cancer in male offspring, including whether exposure mixtures matter. - It uses a Danish nested case-control design, comparing sons who later develop testicular cancer with cancer-free controls. - Researchers will measure prenatal chemical exposure in stored maternal serum and amniotic fluid, and in newborn dried blood spots, looking at substances like DDT/DDE, PCBs, PBDEs, PFAS, phthalates, triclosan, and cotinine. - The study will identify cases and controls through national registries and analyze the associations using statistical models and metabolomics profiling. - Eligibility is males with available stored maternal samples; exclusions include having another cancer, and controls must be cancer-free; the study is currently not recruiting (ACTIVE_NOT_RECRUITING).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PIONEER Initiative is testing a system to provide functional precision medicine testing on a patient’s tumor tissue, which can include organoid drug screening and genomic profiling to help guide therapy decisions. It is for all cancer patients and for people at risk of cancer, at any medical facility, with tumor tissue collected at biopsy or surgery and stored for current or future testing. The study aims to learn whether researchers can return the test results to the patient and their clinicians, and whether this information provides added benefit over standard care. Exclusions include patients who decline definitive therapies, those with comorbidities that prevent definitive therapies, and patients on hospice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers is being studied. Conditions: Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma +8 • Eligibility: Inclusion Criteria: 1. Subjects must have histologic confirmation of advanced, biopsy-accessible, measurable cancers of the following histologies: * Non-viral-associated head and neck squamous cell carcinoma (HNSCC) or human…. Goal: This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ludwig Institute for Cancer Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.